EN
0
Home > Products > Pharmaceuticals & Life Science > API & Advanced Intermediates > (S)-Crizotinib
(S)-Crizotinib structure, CAS 1374356-45-2

(S)-Crizotinib

CAS Number1374356-45-2

Synonyms(S)-Crizotinib; (S)-crizotinib

Molecular FormulaC21H22Cl2FN5O

Molecular Weight450.33700

Purity

Density

Boiling Point

Melting Point

Flash Point

Appearancepowder

EINECS

MSDSChineseEnglish

Symboltransportation

Signal WordWarning

Cat. No.: 2A-2195918 Purity:
Change View

Please Login or Create an Account to: See VlP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

Inquiry

Quality Control of [ 1374356-45-2 ] SDS Specification MoL

COA NMR CNMR HPLC LC-MS
Chemical & Physical Properties
CAS Number1374356-45-2
Catalog No.2A-2195918
Chinese Name(S)-Crizotinib
Synonyms(S)-Crizotinib; (S)-crizotinib
Molecular FormulaC21H22Cl2FN5O
Molecular Weight450.33700
Appearancepowder
Storage Condition-20℃
Application(S)-Crizotinib is the (S)-enantiomer of crizotinib, a potent and selective MTH1 (mutT homolog) inhibitor with an IC50 of 330 nM. (S)-Crizotinib disrupts the homeostasis of the nucleotide pool by inhib
PubChem ID134449836
SMILESCC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
InChIInChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m0/s1
InChI KeyKTEIFNKAUNYNJU-LBPRGKRZSA-N
Hazard Symbolstransportation
MSDSmsds/197647_2_1374356_45_2.pdf
Bioactivity(S)-Crizotinib, a (S)-enantiomer of crizotinib, is a potent and selective MTH1 (mutT homologue) inhibitor with an IC50 of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models[1]. Related Catalog Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Target IC50: 330 nM (MTH1)[1] In Vitro (S)-crizotinib (0.625-80 μM; 24 hours) decreases the viability of NCI-H460, H1975 and A549 cells with IC50 values of 14.29, 16.54 and 11.25 μM, respectively[2]. (S)-crizotinib (10-30 μM; 24 hours) induces NCI-H460, H1975 and A549 cells apoptosis[2]. (S)-crizotinib (10-30 μM; 24 hours) decreases Bcl-2: Bax ratio. (S)-crizotinib decreases B cell lymphoma 2 (Bcl-2), and Bcl-2 associated protein x (Bax) is either unaltered (H460 cells) or shows an increase (H1975 cells)[2]. (S)-Crizotinib induces apoptosis in human non-small cell lung cancer (NSCLC) cells by activating ROS-dependent ER stress apoptotic pathway independent of mutT homologue (MTH1)[2]. Cell Viability Assay[2] Cell Line: NSCLC cells, NCI-H460, H1975 and A549 cells Concentration: 0.625, 1.25, 2.5, 5, 10, 20, 40, 60, 80 μM Incubation Time: 24 hours Result: Decreased the viability of NCI-H460, H1975 and A549 cells with IC50 values of 14.29, 16.54 and 11.25 μM, respectively. Apoptosis Analysis[2] Cell Line: NSCLC cells, NCI-H460, H1975 and A549 cells Concentration: 10, 20 or 30 μM Incubation Time: 24 hours Result: Induced cells apoptosis. Western Blot Analysis[2] Cell Line: NSCLC cells, NCI-H460, H1975 and A549 cells Concentration: 10, 20 or 30 μM Incubation Time: 24 hours Result: Decreased Bcl-2: Bax ratio. In Vivo (S)-crizotinib (7.5 or 15 mg/kg; intraperitoneal injections; once daily for 10 days) results in significant reductions in both tumor volume and tumor weight[2]. Animal Model: Five-week-old, athymic BALB/c nu/nu female mice (17-19 g) with NCI-H460 cells[2] Dosage: 7.5 or 15 mg/kg Administration: Intraperitoneal injections; once daily for 10 days Result: Resulted in significant reductions in both tumor volume and tumor weight. References [1]. Huber KV, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508(7495):222-7. [2]. Dai X, et al. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. J Exp Clin Cancer Res. 2017 Sep 7;36(1):120. Chemical & Physical Properties Molecular Formula C21H22Cl2FN5O Molecular Weight 450.33700 Exact Mass 449.11900 PSA 77.99000 LogP 5.94770 InChIKey KTEIFNKAUNYNJU-LBPRGKRZSA-N SMILES CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl Storage condition -20℃
Use of(S)-Crizotinib, a (S)-enantiomer of crizotinib, is a potent and selective MTH1 (mutT homologue) inhibitor with an IC50 of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models[1]. Properties Name 2-Pyridinamine, 3-[(1S)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl] Synonym More Synonyms (S)-Crizotinib Biological Activity Description (S)-Crizotinib, a (S)-enantiomer of crizotinib, is a potent and selective MTH1 (mutT homologue) inhibitor with an IC50 of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models[1]. Related Catalog Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer IC50: 330 nM (MTH1)[1] References [1]. Huber KV, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508(7495):222-7. [2]. Dai X, et al. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. J Exp Clin Cancer Res. 2017 Sep 7;36(1):120. Chemical & Physical Properties Exact Mass 449.11900 PSA 77.99000 LogP 5.94770 InChIKey KTEIFNKAUNYNJU-LBPRGKRZSA-N Storage condition -20℃
Transport InfoShipping Name: UN
MSDS Transport InfoModule 14. Shipping information European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available
Related Products in API & Advanced Intermediates
Linezolid Desacetamide Descarbonyl2512195-95-62A-2195774
17a-Hydroxyprogesterone acetate320-23-82A-2195777
Capmatinib hydrochloride1865733-40-92A-1195825
Upadacitinib hemihydrate2050057-56-02A-1195840
Dihydroxy Oxaliplatin-Pt(IV)111321-67-62A-1195842
Docetaxel148408-66-52A-2195923
Ofloxacin Dihydrooxazole Impurity2489671-28-32A-1195970
Dexamethasone Dipropionate2A-21960192A-2196019
Prednisone Base2A-21960212A-2196021
Tetrahydro FuroseMide4793-38-82A-1196087
Browse all API & Advanced Intermediates products »
Contact Us

Phone:

630-322-8886

630-322-8887

Email:

[email protected]

Office Locations:

Chicago, IL, USA

San Francisco, CA, USA